Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 9.85% is 158% above its 5-year average of -16.86%, near the high end of its 5-year range (-64.85%–40.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 453.93% above its 12-month average of -2.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 9.85%.
RETURN ON EQUITY (ROE)
9.85%
RETURN ON EQUITY (ROE) AVG TTM
-2.78%
RETURN ON EQUITY (ROE) AVG 3Y
0.82%
RETURN ON EQUITY (ROE) AVG 5Y
-16.86%
RETURN ON EQUITY (ROE) AVG 10Y
-37.13%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+453.93%
CURRENT VS 3Y AVG
+1098.46%
CURRENT VS 5Y AVG
+158.44%
CURRENT VS 10Y AVG
+126.53%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 658 covered companies
CURRENT VS SECTOR MEDIAN
+124.44%
vs the sector median at left
Protagonist Therapeutics, Inc.
Market Cap
$8.88B
Return on Equity (ROE)
9.85%
TTM Avg
-2.78%
3Y Avg
0.82%
5Y Avg
-16.86%
Market Cap
$8.99B
Return on Equity (ROE)
-230.05%
TTM Avg
-355.61%
3Y Avg
-251.82%
5Y Avg
-322.00%
Market Cap
$9.00B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$8.77B
Return on Equity (ROE)
-68.73%
TTM Avg
-161.81%
3Y Avg
-110.86%
5Y Avg
-82.70%
Market Cap
$8.58B
Return on Equity (ROE)
-19.85%
TTM Avg
-23.25%
3Y Avg
-28.82%
5Y Avg
-25.53%
Market Cap
$9.29B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$9.39B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$9.51B
Return on Equity (ROE)
-38.59%
TTM Avg
-21.29%
3Y Avg
-24.61%
5Y Avg
-26.58%
Market Cap
$8.42B
Return on Equity (ROE)
26.84%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.88B | 9.85% | -2.78% | 0.82% | -16.86% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.99B | -230.05% | -355.61% | -251.82% | -322.00% |
| Bruker Corporation (BRKRP)vs › | $9.00B | -2.97% | 3.00% | 15.91% | 17.66% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.77B | -68.73% | -161.81% | -110.86% | -82.70% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.58B | -19.85% | -23.25% | -28.82% | -25.53% |
| Bruker Corporation (BRKR)vs › | $9.29B | -2.97% | 3.00% | 15.91% | 17.66% |
| Insulet Corp. (PODD)vs › | $9.39B | 26.39% | 25.41% | 19.99% | 14.02% |
| Vaxcyte, Inc. (PCVX)vs › | $9.51B | -38.59% | -21.29% | -24.61% | -26.58% |
| Oscar Health, Inc. (OSCR)vs › | $8.42B | 26.84% | -21.41% | -36.14% | -25.75% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.71B | 17.77% | 13.11% | 0.20% | -3.65% |
ROE
9.9%
ROA
9.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 9.85% |
| 2026-03-31 | -17.50% |
| 2025-12-31 | -21.17% |
| 2025-09-30 | 7.11% |
| 2025-06-30 | 7.79% |
| 2025-03-31 | 8.16% |
| 2024-12-31 | 40.75% |
| 2024-09-30 | 32.12% |
| 2024-06-30 | 31.40% |
| 2024-03-31 | 28.93% |
| 2023-12-31 | -23.45% |
| 2023-09-30 | -46.49% |
| 2023-06-30 | -46.80% |
| 2023-03-31 | -64.85% |
| 2022-12-31 | -59.09% |
| 2022-09-30 | -53.41% |
| 2022-06-30 | -49.51% |
| 2022-03-31 | -40.59% |
| 2021-12-31 | -41.85% |
| 2021-09-30 | -32.62% |
| 2021-06-30 | -22.80% |
| 2021-03-31 | -27.02% |
| 2020-12-31 | -23.66% |
| 2020-09-30 | -38.19% |
| 2020-06-30 | -43.83% |
| 2020-03-31 | -132.71% |
| 2019-12-31 | -96.53% |
| 2019-09-30 | -77.13% |
| 2019-06-30 | -78.13% |
| 2019-03-31 | -44.99% |
| 2018-09-30 | -22.68% |
| 2018-06-30 | -22.48% |
| 2018-03-31 | -26.62% |
| 2017-06-30 | -77.69% |
| 2017-03-31 | -52.78% |
| 2016-09-30 | -32.23% |
| 2016-06-30 | -136.17% |
| 2016-03-31 | -90.63% |
| 2015-12-31 | -154.84% |
